Author

C. B. Tilton

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Approach:genetic perturbation / CRISPR· 1 Organism:human· 1 Approach:wet-lab / biochemical assay· 1

Frequent Co-Authors

A. Goodspeed· 1 shared A. Jean· 1 shared C. Deiter· 1 shared D. Theodorescu· 1 shared E. T. Clambey· 1 shared H. Vekony· 1 shared J. C. Costello· 1 shared L. E. Feldman· 1 shared

Activity by Year

2021-2021 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

A. Goodspeed

Mutual co-authors in cluster

Author profile →

1 paper

Recent·Most cited

Cancer BiologybioRxivPreprintMar 4, 2021

NPEPPS is a novel and druggable driver of platinum resistance

R. T. Jones, M. Scholtes, A. Goodspeed…·J. C. Costello

This study identifies NPEPPS as a driver of cisplatin resistance in bladder cancer and shows its inhibition can enhance cisplatin efficacy in preclinical models.

DOI 10.1101/2021.03.04.433676

humanbulk RNA-seq

𝕏 PostBluesky